Product Description
Mechanisms of Action: IL10 Analogue
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Renovo
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2009-017400-91 | P2 |
Completed |
Unknown |
2012-01-10 |
2022-03-13 |
Treatments |
|
| Interleukin-10 | P2 |
Completed |
Injuries/wounds Unspecified |
2006-11-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|